Colposcopic Biopsy Results of HPV 16 and 18 patients in Bartın Op. Dr. Görker sel Bartın state hospıtal obstetrıcs and gynaecology Tjod ebcog congress, May, 2017

Introduction Worldwide, cervical cancer is the second most common and the fifth deadliest cancer in women. It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year. Virtually all cases of cervical cancer are caused by Human papillomavirus (HPV), and just two HPV types, 16 and 18, are responsible for about 70% of all cases. 

Co-testing with cytology and HPV testing at 5-year intervals is now the preferred or acceptable strategy for cervical cancer screening for women aged 30-64 years. HPV testing refers only to testing for high-risk (oncogenic) HPV types. Testing for low-risk (nononcogenic) HPV types has no role in the evaluation of women with abnormal cervical cytologic results. Women with HPV-16 and HPV-18 are at particular risk for CIN 3+

According to American Society for Colposcopy and Cervical Pathology Consensus (ASCCP) guidelines HPV 16 or 18 testsa are positive, colposcopy is recommended.

Method We collected our data of colposcopic biopsy results of HPV 16 and 18 patients admitted to Bartın State Hospital, retrospectively for about 3 years. 231 patients with HPV 16, 48 patients with HPV 18 admitted to gynecology department. Biopsy was performed in 110 patients with HPV 16, 19 patients with HPV 18.

Results HPV 16 patients Biopsy results Number of patients Cytology MEAN AGE Normal 99 (90.8%) 5 ASCUS/15 LSIL/ 26 N/53 INF 43.7 CIN I 2 (1.8%) LSIL/N 37, 41; 39 CIN II LSIL/ASCUS 33, 40; 36.5 CIN III 6 (5.4%) 2 AGC/4 INF 42 CIS 1 (0.9%) LSIL 41 Results HPV 18 patients Biopsy results Number of patients Cytology MEAN AGE Normal 17 (89.4%) LSIL/14 INF/2 N 43.3 CIN I 1 (5.2%) INF 61 CIN II - CIN III 36 CIS

Conclusion Further population based prospective multicenter studies are necessary to determine more precise biopsy results of HR HPV patients. Nonetheless, our results may provide baseline information about the histologic findings of HR HPV positive patients.

Thank you for your attention Bartın-İnkumu